Department of Cardiology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Department of Cardiology, Catharina Hospital, Eindhoven, The Netherlands.
Catheter Cardiovasc Interv. 2021 May 1;97(6):1270-1278. doi: 10.1002/ccd.29439. Epub 2020 Dec 21.
To study safety and performance of the MANTA Vascular closure device (VCD) under real world conditions in 10 centers.
The MANTA is a novel plug-based device for large bore arteriotomy closure.
We included all eligible patients who underwent transfemoral large bore percutaneous procedures. Exclusion criteria were per operator's discretion and included severe calcification or marked tortuosity of the access vessel, presence of marked obesity/cachexia or a systolic blood pressure above 180 mmHg. The primary performance endpoint was time to hemostasis. Primary and secondary safety endpoints were major and minor access site related vascular complications up to 30 days, respectively. Vascular complications were adjudicated by an independent clinical event committee according to VARC-2 criteria. We performed multivariable logistic regression to estimate the effect of baseline and procedural characteristics on any and major vascular complications.
Between February 2018 and July 2019 500 patients were enrolled undergoing Transcatheter aortic valve replacement (TAVR, N = 496), Balloon aortic valvuloplasty (BAV, N = 2), Mechanical circulatory support (MCS, N = 1) or Endovascular aneurysm repair (EVAR, N = 1). Mean age was 80.8 ± 6.6 years with a median STS-score of 2.7 [IQR 2.0-4.3] %. MANTA access site complications were major in 20 (4%) and minor in 28 patients (5.6%). Median time to hemostasis was 50 [IQR 20-120] sec. Severe femoral artery calcification, scar presence in groin, longer procedure duration, female gender and history of hypertension were independent predictors for vascular complications.
In this study, MANTA appeared to be a safe and effective device for large bore access closure under real-world conditions.
在 10 个中心研究 MANTA 血管闭合装置(VCD)在真实环境下的安全性和性能。
MANTA 是一种用于大口径动脉切开术闭合的新型塞子式装置。
我们纳入了所有接受经股大口径经皮操作的合格患者。排除标准由操作者自行决定,包括严重的钙化或明显的入路血管迂曲、明显肥胖/恶病质或收缩压高于 180mmHg。主要性能终点是止血时间。主要和次要安全性终点分别为 30 天内主要和次要入路相关血管并发症。血管并发症根据 VARC-2 标准由独立临床事件委员会进行裁决。我们进行多变量逻辑回归分析,以评估基线和操作特征对任何和主要血管并发症的影响。
2018 年 2 月至 2019 年 7 月,500 例患者接受了经导管主动脉瓣置换术(TAVR,N=496)、球囊主动脉瓣成形术(BAV,N=2)、机械循环支持(MCS,N=1)或血管内动脉瘤修复术(EVAR,N=1)。平均年龄为 80.8±6.6 岁,中位 STS 评分 2.7[IQR 2.0-4.3]%。MANTA 入路部位并发症主要有 20 例(4%),次要并发症有 28 例(5.6%)。止血时间中位数为 50[IQR 20-120]秒。严重股动脉钙化、腹股沟有疤痕、手术时间延长、女性和高血压病史是血管并发症的独立预测因素。
在这项研究中,MANTA 在真实环境下用于大口径入路闭合似乎是一种安全有效的装置。